CELL INTELLIGENCE · 肿瘤细胞治疗研究

癌症免疫治疗学会（SITC）关于急性白血病免疫治疗的临床实践指南，2.0 版

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.

靶向白血病干细胞的脂质体纳米免疫疗法通过沉默 B 细胞淋巴瘤 2 逆转免疫逃逸并抑制融合癌蛋白驱动的急性髓系白血病

Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silen

接受 CAR-T 细胞治疗或其他系统性抗肿瘤治疗的多发性骨髓瘤患者的第二原发恶性肿瘤风险：一项真实世界对比研究

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Co

在这一随访时间相对较短的真实世界数据集中，与其他全身性抗肿瘤治疗相比，多发性骨髓瘤患者在接受 CAR-T 治疗后似乎具有更高的血液系统第二原发恶性肿瘤风险。

靶向 BLVRB 克服单核细胞性急性髓系白血病中的免疫抑制并增强免疫治疗

Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia.

CD84 表达可区分维奈克拉治疗反应并揭示耐药急性髓系白血病中的可靶向脆弱点

CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia.

分泌抗 CD73 scFv 的增强型 CD33 CAR-NK 细胞克服腺苷介导的免疫抑制并提高抗 AML 疗效

Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy.

CD33-CD73 双靶向 CAR-NK 平台协同靶向 AML 细胞和富含腺苷的肿瘤微环境，展现出更优的抗白血病疗效。

高亲和力组织蛋白酶 G 特异性 CAR-T 细胞治疗急性髓系白血病

High-avidity cathepsin-G-specific CAR T cells for the treatment of acute myeloid leukemia.

装载靶向组织蛋白酶 G 的双 HLA 限制性 TCR 的 T 细胞可有效根除 AML

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

组织蛋白酶 G 拓展 CAR-T 疗法在 AML 中的应用范围

Cathepsin-G expands the reach of CAR-T therapy in AML.

BE-CAR33——一种用于急性髓系白血病的「现货型」碱基编辑 CAR33 T 细胞疗法——的 I 期可行性试验

A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia.